Merck KGaA, the German science and technology group, has raised its profit outlook for 2026 for the third time this year, following a solid third quarter and its recent acquisition of Bio-Techne's life-science tools business. The company now expects adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of between €6.2 billion and €6.4 billion, up from its previous range of €5.9 billion to €6.3 billion.
The upgrade comes after third-quarter revenue rose 5.8% year over year to €5.6 billion, while adjusted EBITDA edged up 0.8% to €1.7 billion. Management pointed to favorable foreign-exchange movements and steady demand across its diversified portfolio, which spans healthcare, life sciences, and electronics.
What is driving the improvement?
Merck KGaA's business is often described as an "integrated" mix, meaning it sells everything from pharmaceutical drugs and laboratory equipment to specialty chemicals used in semiconductors. That breadth helped cushion the company against weakness in any single market.
The Bio-Techne deal, announced earlier this year, is a key part of the strategy. Bio-Techne makes tools and reagents used in biomanufacturing and research, a segment that has seen steady demand as drugmakers and academic labs continue to invest in new therapies. By adding those products to its portfolio, Merck KGaA is betting on long-term growth in the life-science tools market, which tends to be less cyclical than some other industrial sectors.
Foreign exchange also played a role. A weaker euro can boost the value of sales made in other currencies when converted back to euros, and management said currency movements were favorable during the quarter.
What does this mean for investors?
For everyday investors, a company raising its profit guidance is generally a positive signal. It suggests that management is confident enough in the current momentum to promise higher earnings to shareholders. Merck KGaA's repeated upgrades this year—now three in total—indicate that the company is performing better than its own initial expectations.
However, it's worth noting that adjusted EBITDA is a non-standard profit measure. It strips out one-off items, such as restructuring costs or acquisition-related expenses, which can make the underlying performance look cleaner than the final net profit figure. Investors should still look at the full income statement to see how those adjustments affect the bottom line.
The company's diversified model also means that its fortunes are tied to several different industries. While life sciences and healthcare are generally seen as defensive areas, the electronics division is more exposed to the cyclical semiconductor market. A downturn in chip demand could weigh on that part of the business, even if the overall outlook remains positive.
Broader market context
Merck KGaA is not the only company to raise its profit outlook recently. Across Europe, several firms have upgraded guidance as they navigate a mixed economic environment. For example, SMA Solar also lifted its 2026 profit outlook on steady rooftop demand, and SBM Offshore raised its forecasts again on strong demand for floating production vessels. These upgrades suggest that some sectors are holding up well despite broader concerns about inflation and interest rates.
In the tech and industrial space, Foxconn's profit beat shows AI servers are carrying the load, highlighting how artificial intelligence is driving demand for certain components. Merck KGaA's electronics division, which supplies materials for chipmaking, could benefit from that trend as well.
Still, not every company is enjoying the same tailwinds. Naver's AI push squeezed profits as its core platform growth slowed, a reminder that heavy investment in new technologies can weigh on near-term earnings.
What to watch next
Investors will be watching whether Merck KGaA can maintain this momentum into 2026. The company's ability to hit the top end of its new range will depend on continued demand for its life-science tools, stable currency conditions, and no major disruptions in its pharmaceutical pipeline.
Another key factor is the integration of Bio-Techne. Acquisitions often come with integration risks, and investors will want to see that the deal delivers the expected synergies without hurting margins.
For now, the raised guidance is a clear sign that Merck KGaA's management sees more upside than risk in the year ahead. But as with any investment, it's important to consider the company's full financial picture and how it fits into your own portfolio strategy.
